(BIM) Biomerieux - Overview
Exchange: PA •
Country: France •
Currency: EUR •
Type: Common Stock •
ISIN: FR0013280286
Stock: Diagnostic Tests, Culture Media, Monitoring Systems, Data Software
Total Rating 41
Risk 94
Buy Signal -1.09
| Risk 5d forecast | |
|---|---|
| Volatility | 22.6% |
| Relative Tail Risk | -7.96% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.92 |
| Alpha | -20.26 |
| Character TTM | |
|---|---|
| Beta | 0.081 |
| Beta Downside | 0.011 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.14% |
| CAGR/Max DD | 0.01 |
Description: BIM Biomerieux March 04, 2026
bioMérieux S.A. (BIM) is a French in vitro diagnostics company specializing in infectious diseases. It operates globally across clinical and industrial applications.
The companys product portfolio includes a wide range of diagnostic solutions. Key offerings include chromogen culture media (CHROMID RANGE), blood culture systems (BACT/ALERT VIRTUO), and polymerase chain reaction (PCR) systems (BIOFIRE, BIOFIRE SPOTFIRE). PCR is a fundamental technology in molecular diagnostics, enabling rapid and accurate detection of pathogens.
BIM also provides mass spectrometry (VITEK MS) and automated identification and antimicrobial susceptibility testing (VITEK 2) systems. Antimicrobial susceptibility testing is crucial for guiding appropriate antibiotic treatment and combating antimicrobial resistance, a significant global health challenge.
Additional products include DNA/RNA extraction reagents (EMAG, NUCLISENS), solutions for food industry microorganism detection (GENE-UP, VERIFLOW), and various microbiology instruments (CHEMUNEX, TEMPO). The company also offers software for diagnostic support (Biomérieux vision suite) and laboratory consultancy services.
For more in-depth data and analysis, consider exploring ValueRays comprehensive research tools.
Headlines to watch out for
- Infectious disease diagnostics demand drives clinical segment revenue
- Industrial microbiology solutions sustain growth in food safety
- Regulatory approvals for new diagnostic platforms impact market access
- Competition in PCR and mass spectrometry segments pressures pricing
- Global health crises increase demand for rapid diagnostic testing
Piotroski VR‑10 (Strict, 0-10) 8.5
| Net Income: 681.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 10.11 > 1.0 |
| NWC/Revenue: 21.29% < 20% (prev 21.73%; Δ -0.44% < -1%) |
| CFO/TA 0.26 > 3% & CFO 1.46b > Net Income 681.4m |
| Net Debt (-108.4m) to EBITDA (1.60b): -0.07 < 3 |
| Current Ratio: 2.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (119.0m) vs 12m ago 0.33% < -2% |
| Gross Margin: 53.06% > 18% (prev 0.53%; Δ 5254 % > 0.5%) |
| Asset Turnover: 127.3% > 50% (prev 104.8%; Δ 22.44% > 0%) |
| Interest Coverage Ratio: 41.54 > 6 (EBITDA TTM 1.60b / Interest Expense TTM 22.6m) |
Altman Z'' 3.42
| A: 0.26 (Total Current Assets 2.54b - Total Current Liabilities 1.06b) / Total Assets 5.57b |
| B: 0.07 (Retained Earnings 397.5m / Total Assets 5.57b) |
| C: 0.17 (EBIT TTM 940.9m / Avg Total Assets 5.45b) |
| D: 0.28 (Book Value of Equity 409.5m / Total Liabilities 1.47b) |
| Altman-Z'' Score: 3.42 = A |
Beneish M -3.16
| DSRI: 0.92 (Receivables 1.01b/888.6m, Revenue 6.93b/5.58b) |
| GMI: 0.99 (GM 53.06% / 52.57%) |
| AQI: 0.86 (AQ_t 0.25 / AQ_t-1 0.29) |
| SGI: 1.24 (Revenue 6.93b / 5.58b) |
| TATA: -0.14 (NI 681.4m - CFO 1.46b) / TA 5.57b) |
| Beneish M-Score: -3.16 (Cap -4..+1) = AA |
What is the price of BIM shares?
As of March 11, 2026, the stock is trading at EUR 95.05 with a total of 153,557 shares traded.
Over the past week, the price has changed by -3.80%, over one month by +0.74%, over three months by -9.04% and over the past year by -18.57%.
Over the past week, the price has changed by -3.80%, over one month by +0.74%, over three months by -9.04% and over the past year by -18.57%.
Is BIM a buy, sell or hold?
Biomerieux has no consensus analysts rating.
What are the forecasts/targets for the BIM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 116.5 | 22.6% |
| Analysts Target Price | - | - |
BIM Fundamental Data Overview March 10, 2026
Market Cap USD = 12.97b (11.26b EUR * 1.1513 EUR.USD)
P/E Trailing = 28.5629
P/E Forward = 20.5339
P/S = 2.7676
P/B = 2.7458
P/EG = 1.3769
Revenue TTM = 6.93b EUR
EBIT TTM = 940.9m EUR
EBITDA TTM = 1.60b EUR
Long Term Debt = 212.8m EUR (from longTermDebt, two quarters ago)
Short Term Debt = 131.4m EUR (from shortTermDebt, last quarter)
Debt = 461.4m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -108.4m EUR (from netDebt column, last quarter)
Enterprise Value = 11.16b EUR (11.26b + Debt 461.4m - CCE 569.8m)
Interest Coverage Ratio = 41.54 (Ebit TTM 940.9m / Interest Expense TTM 22.6m)
EV/FCF = 14.40x (Enterprise Value 11.16b / FCF TTM 774.5m)
FCF Yield = 6.94% (FCF TTM 774.5m / Enterprise Value 11.16b)
FCF Margin = 11.17% (FCF TTM 774.5m / Revenue TTM 6.93b)
Net Margin = 9.83% (Net Income TTM 681.4m / Revenue TTM 6.93b)
Gross Margin = 53.06% ((Revenue TTM 6.93b - Cost of Revenue TTM 3.25b) / Revenue TTM)
Gross Margin QoQ = 49.00% (prev 57.09%)
Tobins Q-Ratio = 2.00 (Enterprise Value 11.16b / Total Assets 5.57b)
Interest Expense / Debt = 1.63% (Interest Expense 7.50m / Debt 461.4m)
Taxrate = 24.39% (76.2m / 312.4m)
NOPAT = 711.4m (EBIT 940.9m * (1 - 24.39%))
Current Ratio = 2.39 (Total Current Assets 2.54b / Total Current Liabilities 1.06b)
Debt / Equity = 0.11 (Debt 461.4m / totalStockholderEquity, last quarter 4.10b)
Debt / EBITDA = -0.07 (Net Debt -108.4m / EBITDA 1.60b)
Debt / FCF = -0.14 (Net Debt -108.4m / FCF TTM 774.5m)
Total Stockholder Equity = 4.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.51% (Net Income 681.4m / Total Assets 5.57b)
RoE = 16.92% (Net Income TTM 681.4m / Total Stockholder Equity 4.03b)
RoCE = 22.19% (EBIT 940.9m / Capital Employed (Equity 4.03b + L.T.Debt 212.8m))
RoIC = 16.94% (NOPAT 711.4m / Invested Capital 4.20b)
WACC = 6.01% (E(11.26b)/V(11.73b) * Re(6.21%) + D(461.4m)/V(11.73b) * Rd(1.63%) * (1-Tc(0.24)))
Discount Rate = 6.21% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 0.01%
[DCF] Terminal Value 88.03% ; FCFF base≈545.2m ; Y1≈672.6m ; Y5≈1.15b
[DCF] Fair Price = 272.9 (EV 32.11b - Net Debt -108.4m = Equity 32.22b / Shares 118.1m; r=6.01% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -9.53 | EPS CAGR: -47.24% | SUE: 0.0 | # QB: 0
Revenue Correlation: 22.56 | Revenue CAGR: 8.77% | SUE: -0.04 | # QB: 0
EPS current Year (2026-12-31): EPS=4.72 | Chg7d=-0.104 | Chg30d=-0.137 | Revisions Net=-6 | Growth EPS=+1.8% | Growth Revenue=+4.7%
EPS next Year (2027-12-31): EPS=5.36 | Chg7d=-0.041 | Chg30d=-0.070 | Revisions Net=-6 | Growth EPS=+13.5% | Growth Revenue=+7.2%
[Analyst] Revisions Ratio: -1.00 (0 Up / 6 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 4.4% (Discount Rate 7.9% - Earnings Yield 3.5%)
[Growth] Growth Spread = +2.7% (Analyst 7.2% - Implied 4.4%)
P/E Trailing = 28.5629
P/E Forward = 20.5339
P/S = 2.7676
P/B = 2.7458
P/EG = 1.3769
Revenue TTM = 6.93b EUR
EBIT TTM = 940.9m EUR
EBITDA TTM = 1.60b EUR
Long Term Debt = 212.8m EUR (from longTermDebt, two quarters ago)
Short Term Debt = 131.4m EUR (from shortTermDebt, last quarter)
Debt = 461.4m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -108.4m EUR (from netDebt column, last quarter)
Enterprise Value = 11.16b EUR (11.26b + Debt 461.4m - CCE 569.8m)
Interest Coverage Ratio = 41.54 (Ebit TTM 940.9m / Interest Expense TTM 22.6m)
EV/FCF = 14.40x (Enterprise Value 11.16b / FCF TTM 774.5m)
FCF Yield = 6.94% (FCF TTM 774.5m / Enterprise Value 11.16b)
FCF Margin = 11.17% (FCF TTM 774.5m / Revenue TTM 6.93b)
Net Margin = 9.83% (Net Income TTM 681.4m / Revenue TTM 6.93b)
Gross Margin = 53.06% ((Revenue TTM 6.93b - Cost of Revenue TTM 3.25b) / Revenue TTM)
Gross Margin QoQ = 49.00% (prev 57.09%)
Tobins Q-Ratio = 2.00 (Enterprise Value 11.16b / Total Assets 5.57b)
Interest Expense / Debt = 1.63% (Interest Expense 7.50m / Debt 461.4m)
Taxrate = 24.39% (76.2m / 312.4m)
NOPAT = 711.4m (EBIT 940.9m * (1 - 24.39%))
Current Ratio = 2.39 (Total Current Assets 2.54b / Total Current Liabilities 1.06b)
Debt / Equity = 0.11 (Debt 461.4m / totalStockholderEquity, last quarter 4.10b)
Debt / EBITDA = -0.07 (Net Debt -108.4m / EBITDA 1.60b)
Debt / FCF = -0.14 (Net Debt -108.4m / FCF TTM 774.5m)
Total Stockholder Equity = 4.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.51% (Net Income 681.4m / Total Assets 5.57b)
RoE = 16.92% (Net Income TTM 681.4m / Total Stockholder Equity 4.03b)
RoCE = 22.19% (EBIT 940.9m / Capital Employed (Equity 4.03b + L.T.Debt 212.8m))
RoIC = 16.94% (NOPAT 711.4m / Invested Capital 4.20b)
WACC = 6.01% (E(11.26b)/V(11.73b) * Re(6.21%) + D(461.4m)/V(11.73b) * Rd(1.63%) * (1-Tc(0.24)))
Discount Rate = 6.21% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 33.33 | Cagr: 0.01%
[DCF] Terminal Value 88.03% ; FCFF base≈545.2m ; Y1≈672.6m ; Y5≈1.15b
[DCF] Fair Price = 272.9 (EV 32.11b - Net Debt -108.4m = Equity 32.22b / Shares 118.1m; r=6.01% [WACC]; 5y FCF grow 25.0% → 2.90% )
EPS Correlation: -9.53 | EPS CAGR: -47.24% | SUE: 0.0 | # QB: 0
Revenue Correlation: 22.56 | Revenue CAGR: 8.77% | SUE: -0.04 | # QB: 0
EPS current Year (2026-12-31): EPS=4.72 | Chg7d=-0.104 | Chg30d=-0.137 | Revisions Net=-6 | Growth EPS=+1.8% | Growth Revenue=+4.7%
EPS next Year (2027-12-31): EPS=5.36 | Chg7d=-0.041 | Chg30d=-0.070 | Revisions Net=-6 | Growth EPS=+13.5% | Growth Revenue=+7.2%
[Analyst] Revisions Ratio: -1.00 (0 Up / 6 Down within 30d for Current Year)
[Growth] Implied Growth Rate = 4.4% (Discount Rate 7.9% - Earnings Yield 3.5%)
[Growth] Growth Spread = +2.7% (Analyst 7.2% - Implied 4.4%)